Literature DB >> 22113354

Abnormal levels of antioxidant defenses in a large sample of patients with hypertensive disorders of pregnancy.

Maria Luisa Miranda Guisado1, Antonio J Vallejo-Vaz, Pablo Stiefel García Junco, Luis Jiménez Jiménez, Salvador García Morillo, Ovidio Muñiz Grijalvo, Verónica Alfaro Lara, José Villar Ortiz, Encarnación Pamies-Andréu.   

Abstract

Increased levels of oxidative stress have been demonstrated in Preeclampsia in previous studies, but this finding has not been established in other hypertensive disorders in pregnancy (HDP). We measured different markers of lipid peroxidation and antioxidant defenses by spectrophotometry or enzymoimmunoanalysis in 339 pregnant women: 85 with gestational hypertension (GH), 88 chronic hypertension (CH), 104 Preeclampsia and 62 healthy pregnant control women (PCW). Lower activity of superoxide dismutase and higher levels of catalase were found in GH, CH and preeclampsia compared with PCW (964.4±116.5, 970.0±120.4, 971.2±137.5 and 1063.4±133.7 U g(-1) Hb, P<0.001; and 313.0±71.7, 292.2±45.3, 297.1±47.2, 215.5±26.2 U mg(-1) Hb, P<0.0001; respectively). Regarding the glutathione REDOX cycle, we found the following in GH, CH and preeclampsia compared with PCW: a decrease in its reduced form (2.6±0.6, 2.7±0.8, 2.7±0.9, 3.3±1.3 μmol l(-1), P<0.003), a parallel increase in the oxidized form (185.6±68.9, 194.7±75.0, 184.3±78.3, 85.1±27.5 μmol l(-1), P<0.0001) and an increment in glutathione peroxidase (85.9±22.0, 86.4±20.9, 82.1±23.5 and 77.2±19.7 U g(-1) Hb, P<0.04) and glutathione reductase (6384.3±1261.9, 6724.6±1154.1, 6287.9±1399.9 and 6044.4±1208.4 mU g(-1) Hb, P<0.01, respectively). Nitrites/nitrates were higher in patients with preeclampsia than in PCW (31.50±15.08, 26.80±8.39 μmol l(-1), P<0.002). Although malondialdehyde and oxidized-LDL levels were similar among groups, free fatty acids were increased in every HDP (GH 514.6±194.6, CH 501.3±197.4, preeclampsia 555.2±230.1 μmol l(-1)) compared with PCW (351.4±146.1 μmol l(-1)), P<0.0001. Our results show an oxidation/reduction imbalance with an increase in oxidative stress coupled with a decreased capacity of antioxidant systems, not only in preeclampsia but also in every HDP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22113354     DOI: 10.1038/hr.2011.200

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  The Relationship of Restless Legs Syndrome to History of Pregnancy-Induced Hypertension.

Authors:  Kim E Innes; Sahiti Kandati; Kathryn L Flack; Parul Agarwal; Terry Kit Selfe
Journal:  J Womens Health (Larchmt)       Date:  2016-02-25       Impact factor: 2.681

2.  Increased Oxidatively Modified Forms of Albumin in Association with Decreased Total Antioxidant Activity in Different Types of Hypertensive Disorders of Pregnancy.

Authors:  Jyothi M P D'souza; Sindhu Harish; Vinitha Ramanath Pai; Chitra Shriyan
Journal:  Indian J Clin Biochem       Date:  2016-06-07

3.  The Change of Oxidative Stress in Maternal Blood During Pregnancy.

Authors:  Mika Fukase; Norikazu Watanabe; Keiko Yamanouchi; Seiji Tsutsumi; Satoru Nagase
Journal:  Reprod Sci       Date:  2022-01-13       Impact factor: 2.924

4.  New Insights into the Pathogenesis of Preeclampsia - The Role of Nrf2 Activators and their Potential Therapeutic Impact.

Authors:  N Kweider; C J Wruck; W Rath
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

5.  Oxidative Stress Markers Differ in Two Placental Dysfunction Pathologies: Pregnancy-Induced Hypertension and Intrauterine Growth Restriction.

Authors:  Aleksandra Zygula; Przemyslaw Kosinski; Piotr Wroczynski; Magdalena Makarewicz-Wujec; Bronislawa Pietrzak; Mirosław Wielgos; Joanna Giebultowicz
Journal:  Oxid Med Cell Longev       Date:  2020-06-30       Impact factor: 6.543

6.  Evaluation of oxidative stress and antioxidant status in diabetic and hypertensive women during labor.

Authors:  Mashael M Al-Shebly; Mahmoud A Mansour
Journal:  Oxid Med Cell Longev       Date:  2012-07-24       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.